Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: Trastuzumab emtansine
Sponsor: Consorzio Oncotech
Collaborators: Roche Pharma AG